Fig. 1

The One-way Sensitivity Analyses for Serplulimab plus CF Strategy Compared to Placebo plus CF Strategy in the Overall Patients (A), Patients with PD-L1 Expression Level of 1 ≤ CPS < 10 (B), Patients with PD-L1 CPS ≥ 10 (C). Abbreviation: PFS, progression-free survival; PD, progressive disease; CF, cisplatin and 5-fluorouracil; PD-L1, programmed death ligand 1; NCD, Neutrophil count decreased; WBC, White blood cell; AEs, adverse events; QALY, quality-adjusted life-year